Clinical and serological factors associated with lupus pericarditis: a case–control study

Hsieh, Meng-Ru; Chen, Yen-Fu; Chang, Chun‐Shin; Yu, Kuang‐Hui; Fang, Yao-Fan

doi:10.1007/s10067-022-06469-5

Cited by 2 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest prevalence is among those with SLE. Up to 50% of patients with SLE have previously been reported to have some pericardial involvement, [5][6][7] although the definition varies by study and may include incidental pericardial effusions found on imaging or lump pericarditis with other forms of serositis. Symptomatic pericarditis (defined as precordial chest pain, pericardial friction rub, typical ECG abnormalities, or pericardial effusion) occurred in 16.4% of patients with SLE in 1 study.…”

Section: Epidemiologymentioning

confidence: 99%

“…Symptomatic pericarditis (defined as precordial chest pain, pericardial friction rub, typical ECG abnormalities, or pericardial effusion) occurred in 16.4% of patients with SLE in 1 study. 7 However, because there are no clear guidelines for screening for pericarditis in SLE, the true prevalence may be underestimated. Pericarditis can also be seen in other rheumatic conditions such as rheumatoid arthritis (RA), Sjögren's syndrome, systemic sclerosis, systemic vasculitis, and autoinflammatory syndromes.…”

Section: Epidemiologymentioning

confidence: 99%

See 1 more Smart Citation

Evaluation and Management of Pericarditis in Rheumatic Diseases

Kawano,

Pabón,

Feldman

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

This review summarizes the evaluation for underlying rheumatic conditions in patients presenting with acute pericarditis, treatment considerations for specific rheumatic conditions, and the role of imaging in diagnosis and monitoring. Pericarditis may be one of the initial presentations of a rheumatic disease or identified in a patient with known rheumatic disease. There is also growing evidence for using anti-inflammatory and immunosuppressive agents for treating recurrent pericarditis, which can overlap with the treatment of rheumatic diseases.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

Evaluation and Management of Pericarditis in Rheumatic Diseases

Kawano,

Pabón,

Feldman

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

Diagnosis, Risk Stratification, and Treatment of Pericarditis

Cremer,

Klein,

Imazio

2024

JAMA

View full text Add to dashboard Cite

ImportancePericarditis accounts for up to 5% of emergency department visits for nonischemic chest pain in North America and Western Europe. With appropriate treatment, 70% to 85% of these patients have a benign course. In acute pericarditis, the development of constrictive pericarditis (&lt;0.5%) and pericardial tamponade (&lt;3%) can be life-threatening.ObservationsAcute pericarditis is diagnosed with presence of 2 or more of the following: sharp, pleuritic chest pain that worsens when supine (≈90%); new widespread electrocardiographic ST-segment elevation and PR depression (≈25%-50%); a new or increased pericardial effusion that is most often small (≈60%); or a pericardial friction rub (&lt;30%). In North America and Western Europe, the most common causes of acute pericarditis are idiopathic or viral, followed by pericarditis after cardiac procedures or operations. Tuberculosis is the most common cause in endemic areas and is treated with antituberculosis therapy, with corticosteroids considered for associated constrictive pericarditis. Treatment of acute idiopathic and pericarditis after cardiac procedures or operations involves use of high-dose nonsteroidal anti-inflammatory drugs (NSAIDs), with doses tapered once chest pain has resolved and C-reactive protein level has normalized, typically over several weeks. These patients should receive a 3-month course of colchicine to relieve symptoms and reduce the risk of recurrence (37.5% vs 16.7%; absolute risk reduction, 20.8%). With a first recurrence of pericarditis, colchicine should be continued for at least 6 months. Corticosteroids are often used if pericarditis does not improve with NSAIDs and colchicine. In certain patients with multiple recurrences, which can occur for several years, interleukin 1 (IL-1) blockers have demonstrated efficacy and may be preferred to corticosteroids.ConclusionsAcute pericarditis is a common cause of nonischemic chest pain. Tuberculosis is the leading cause of pericarditis in endemic areas and is treated with antitubercular therapy. In North America and Western Europe, pericarditis is typically idiopathic, develops after a viral infection, or develops following cardiac procedures or surgery. Treatment with NSAIDs and colchicine leads to a favorable prognosis in most patients, although 15% to 30% of patients develop recurrence. Patients with multiple recurrent pericarditis can have a disease duration of several years or more, are often treated with corticosteroids, and IL-1 blockers may be used for selected patients as steroid-sparing therapy.

show abstract

Clinical and serological factors associated with lupus pericarditis: a case–control study

Cited by 2 publications

References 31 publications

Evaluation and Management of Pericarditis in Rheumatic Diseases

Evaluation and Management of Pericarditis in Rheumatic Diseases

Diagnosis, Risk Stratification, and Treatment of Pericarditis

Contact Info

Product

Resources

About